Mutation, drift and selection in single-driver hematologic malignancy: Example of secondary myelodysplastic syndrome following treatment of inherited neutropenia.

Autor: Wojdyla T; Systems Engineering Group, Silesian University of Technology, Gliwice, Poland., Mehta H; Department of Pediatrics, Cleveland Clinic, Cleveland, OH, United States of America.; Department of Cancer Biology, Cleveland Clinic, Cleveland, OH, United States of America., Glaubach T; Clinical Pediatrics, Division of Hospital Medicine, Stony Brook Children's Hospital, Stony Brook, New York., Bertolusso R; Department of Statistics, Rice University, Houston, TX, United States of America., Iwanaszko M; Systems Engineering Group, Silesian University of Technology, Gliwice, Poland.; Department of Statistics, Rice University, Houston, TX, United States of America.; Department of Preventive Medicine-Division of Biostatistics, Northwestern University, Chicago, IL United States of America., Braun R; Department of Preventive Medicine-Division of Biostatistics, Northwestern University, Chicago, IL United States of America.; Department of Engineering Sciences and Applied Mathematics, Northwestern University, Evanston, IL United States of America., Corey SJ; Department of Pediatrics, Cleveland Clinic, Cleveland, OH, United States of America.; Department of Cancer Biology, Cleveland Clinic, Cleveland, OH, United States of America.; Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, United States of America., Kimmel M; Systems Engineering Group, Silesian University of Technology, Gliwice, Poland.; Department of Statistics, Rice University, Houston, TX, United States of America.; Department of Bioengineering, Rice University, Houston, TX, United States of America.
Jazyk: angličtina
Zdroj: PLoS computational biology [PLoS Comput Biol] 2019 Jan 07; Vol. 15 (1), pp. e1006664. Date of Electronic Publication: 2019 Jan 07 (Print Publication: 2019).
DOI: 10.1371/journal.pcbi.1006664
Abstrakt: Cancer development is driven by series of events involving mutations, which may become fixed in a tumor via genetic drift and selection. This process usually includes a limited number of driver (advantageous) mutations and a greater number of passenger (neutral or mildly deleterious) mutations. We focus on a real-world leukemia model evolving on the background of a germline mutation. Severe congenital neutropenia (SCN) evolves to secondary myelodysplastic syndrome (sMDS) and/or secondary acute myeloid leukemia (sAML) in 30-40%. The majority of SCN cases are due to a germline ELANE mutation. Acquired mutations in CSF3R occur in >70% sMDS/sAML associated with SCN. Hypotheses underlying our model are: an ELANE mutation causes SCN; CSF3R mutations occur spontaneously at a low rate; in fetal life, hematopoietic stem and progenitor cells expands quickly, resulting in a high probability of several tens to several hundreds of cells with CSF3R truncation mutations; therapeutic granulocyte colony-stimulating factor (G-CSF) administration early in life exerts a strong selective pressure, providing mutants with a growth advantage. Applying population genetics theory, we propose a novel two-phase model of disease development from SCN to sMDS. In Phase 1, hematopoietic tissues expand and produce tens to hundreds of stem cells with the CSF3R truncation mutation. Phase 2 occurs postnatally through adult stages with bone marrow production of granulocyte precursors and positive selection of mutants due to chronic G-CSF therapy to reverse the severe neutropenia. We predict the existence of the pool of cells with the mutated truncated receptor before G-CSF treatment begins. The model does not require increase in mutation rate under G-CSF treatment and agrees with age distribution of sMDS onset and clinical sequencing data.
Competing Interests: The authors have declared that no competing interests exist.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje